

Mangosteen juice blend for the reduction of inflammation in obese subjects

Submission date 21/07/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 19/08/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 19/08/2009	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Jay Udani

Contact details
18250 Roscoe Blvd. Suite 240
Northridge
United States of America
91325

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
XANG1000

Study information

Scientific Title

Mangosteen juice blend for the reduction of inflammation in obese subjects: a randomised, double-blind, placebo-controlled, dose finding study

Study objectives

The hypothesis of this study is that XanGo™ Juice (a proprietary juice blend containing mangosteen juice) will reduce inflammation and increase antioxidant levels in obese subjects.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Institutional Review Board (IRB) approval obtained from the Copernicus Group (Cary, NC) on the 11th July 2007 (ref: MED4-07-299)

Study design

Randomised double-blind placebo-controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Metabolic syndrome/obesity

Interventions

This is a randomised, double-blind, placebo-controlled 8-week study with a 2-week pre-study washout period. The study included four groups including placebo and three doses of test product. The study was conducted at a single site Medicus Research clinical research center, Northridge, CA, USA.

The test product was XanGo™ Juice produced by XanGo, LLC. The primary ingredient was mangosteen (*Garcinia mangostana* L.) whole fruit puree. Other ingredients were apple fruit juice, pear fruit juice, grape fruit juice, pear fruit puree, blueberry fruit juice, raspberry fruit juice, strawberry fruit juice, cranberry fruit juice, and cherry fruit juice. The placebo consisted of water, sucrose (3 g/30 ml), citric acid, red grape juice concentrate, fibre complex, grape skin, natural flavours, red #40, cloud (ester gum), whey protein isolate, sodium benzoate, xanthan gum, blue #1, and caramel color. Three different dosages of the juice were tested and compared to placebo. The product doses tested were 3 oz, 6 oz and 9 oz. All doses and placebo were consumed in a total of 9 oz of liquid in identical bottles. The placebo was used to make up the

volume for the lower doses. Subjects were instructed to consume the assigned drink twice a day, once in the morning and again in the evening. They therefore took a total of 0 to 18 oz of active product per day in 18 oz of fluid for 8 weeks.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

XanGo™ Juice

Primary outcome measure

Efficacy of multiple doses of XanGo™ Juice compared to placebo on inflammation as measured by levels of HS-CRP and cytokines (interleukin [IL]-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha). All outcomes measured at baseline, 4 weeks and 8 weeks.

Secondary outcome measures

Oxidative stress via F2 isoprostane in urine. All outcomes measured at baseline, 4 weeks and 8 weeks.

Overall study start date

01/09/2007

Completion date

01/05/2008

Eligibility**Key inclusion criteria**

1. Aged between 30 - 75 years of age, either sex
2. Body mass index (BMI) greater than 30 and less than 45 kg/m² (obese)
3. A high sensitivity C-reactive protein (HS-CRP) of greater than 3
4. Agreed to discontinue anti-inflammatory medications and supplements (other than daily 81 mg aspirin, which was allowed)
5. Agreed to use approved birth control methods if a female of childbearing age
6. Agreed to not initiate or change any exercise or diet programs during the study

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Key exclusion criteria

1. Subjects were excluded if they had consumed the test product in the past
2. Had allergies to the test product
3. Using any drugs that can affect CRP
4. Were taking hormone replacements, anticoagulants or anti-platelet therapy
5. Had surgery in the past 6 months
6. Smoked cigarettes
7. Known alcohol or drug abuse
8. Had major systemic, inflammatory or chronic disease
9. Untreated depression
10. Active eating disorder
11. Unable to understand or follow study protocol
12. Pregnant or lactating
13. Any medical condition which, in the opinion of the investigator, might interfere with the subject's ability in the trial

Date of first enrolment

01/09/2007

Date of final enrolment

01/05/2008

Locations

Countries of recruitment

United States of America

Study participating centre

18250 Roscoe Blvd. Suite 240

Northridge

United States of America

91325

Sponsor information

Organisation

XanGo, LLC (USA)

Sponsor details

3098 Executive Parkway

Lehi, UT

United States of America

84043

Sponsor type

Industry

Website

<http://www.xango.com/>

ROR

<https://ror.org/041mqc477>

Funder(s)**Funder type**

Industry

Funder Name

XanGo, LLC (USA)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration